Safety Reporting Translation Built for Speed, Accuracy, and Regulatory Compliance
Our approach is built for scalable global safety operations
Safety Reporting Translation for Pharmacovigilance and Post-Market Surveillance
Case processing timelines
Regulatory submission deadlines
Inspection outcomes
Sponsor and authority confidence
Pharmacovigilance and post market surveillance teams operate within strict reporting timelines, expanding geographic coverage, and continuous regulatory oversight.
For pharmaceuticals, serious adverse events must be triaged, translated, reviewed, and reported within defined regulatory timeframes. For medical devices, serious incidents, field safety corrective actions, and trend reporting follow their own mandatory reporting timelines under MDR and IVDR.
Translation is embedded directly within the safety reporting workflow. It must align with regulatory terminology, support accurate case narratives, and integrate seamlessly into validated pharmacovigilance systems and complaint handling processes. Delays or inconsistencies can disrupt case processing or create compliance risk.
Welo Life Sciences combines pharmacovigilance safety trained linguistic expertise with AI enabled automation to accelerate turnaround times, reduce manual effort, and maintain consistent, audit ready delivery at scale across pharmaceutical safety reporting and medical device vigilance programs.
Automated. Fast. Scalable. Built for real safety operations.
Where Welo Life Sciences Fits
Pharmacovigilance and post market surveillance teams operate within fixed reporting timelines, strict regulatory frameworks, and ongoing inspection oversight. Translation is one step within the safety workflow, but when it slows down or introduces inconsistency, the consequences extend far beyond language. Our model is built around three principles that support safety operations under real operational pressure.
Speed-Enabled Compliance
In pharmacovigilance and vigilance reporting, speed must operate alongside control.
We deliver rapid turnaround times aligned with global reporting obligations. This includes expedited pharmaceutical safety reports and serious incident reporting under MDR while maintaining structured quality checks, documented workflows, and traceable processes that support regulatory inspection readiness.
Scalability for Global Safety Operations
Safety programs expand across products, markets, and languages. Workflows must scale without losing consistency.
Our delivery model supports high case volumes and global reporting coverage while preserving terminology accuracy, reporting discipline, and operational stability.
Smarter Safety Workflows
Manual handoffs introduce delay and operational risk.
We integrate into end-to-end safety workflows and apply automation and AI enabled solutions that reduce repetitive effort, accelerate intake and delivery, and support increasingly digital safety operations.
How We Support Your Safety Team
Translation aligned with global safety reporting timelines.
Support includes:
- 6hr turnaround for urgent product complaints and time sensitive safety documentation
- Reliable 8-12-24hr delivery for broader pharmacovigilance documentation
- High-capacity workflows designed for sustained daily case processing volumes
- Delivery timelines aligned with global pharmaceutical and medical device reporting requirements
Technology applied responsibly within regulated safety environments.
Support includes:
- AI- enabled machine translation with expert human validation
- Smart intake and OCR processing for unstructured safety content including emails, PDFs, scans, and screenshots
- Automated workflow routing and document management
- Reduced manual handoffs and improved workflow efficiency
Structured workflows designed for inspection confidence.
Support includes:
- Customizable quality processes aligned with safety and complaint handling standards
- Full audit trails documenting workflow steps and processing timelines
- Standardized templates and terminology management
- Linguists trained in pharmacovigilance and vigilance reporting standards
Operational resilience across markets and time zones.
Support includes:
- Standardization frameworks that maintain consistency as programs expand
- High-capacity workflows built for daily case volume
- Follow the sun delivery model supporting continuous processing
- Consistent delivery across more than fifty global markets
Why Safety Teams Trust Welo Life Sciences
Pharmacovigilance and Vigilance Expertise
Our subject matter experts understand safety language, case narratives, pharmacovigilance workflows, and MDR and IVDR vigilance requirements. We work inside safety operations, not outside of them.
Proven Performance Under Pressure
Urgent product complaint translations delivered in as little as 6 hours. Reliable 12-to-24hr turnaround across more than fifty language pairs for broader pharmacovigilance documentation.
Simultaneous multilingual field safety notice distribution supporting device manufacturers across multiple markets.
Built in Automation
OCR processing for unstructured safety content. Standardized templates and terminology governance. AI enabled workflows with expert human validation. Automation is embedded to reduce manual effort while maintaining regulatory control.
Inspection Ready Workflows
Documented quality processes. Structured quality checks. Full traceable audit trails.
Every workflow step is designed to withstand regulatory authority and competent authority inspection.
Built for the Future of Safety Operations
Safety reporting is evolving as regulators expand digital frameworks and reporting requirements.
As EUDAMED modules become operational and vigilance reporting becomes more integrated, workflows must adapt to increasing complexity and regulatory expectations.
Welo Life Sciences supports this shift through AI-enabled triage, workflow expansion, and scalable processes grounded in real pharmacovigilance operations and compliance requirements.
When Safety Timelines Matter, Precision Matters
PV teams don’t get margin for error. Translation should support compliance, not create risk.